



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pa	atent Applica	ation of:	
Kyung-	shig CHUNG	G, et al.	
Applica	tion No.: 10	0/602,636	Group Art Unit: 2625
Confirm	nation No. 1	070	
Filed: 、	June 25, 200	03	Examiner: Thierry L. PHAM
For:	IMAGE FOR	RMING APPARATUS	
		INFORMATION	DISCLOSURE STATEMENT
PO Box	ssioner for F (1450 dria, VA 223		
Sir:			
provide subject	d certain inf U.S. patent	formation which the Ex t application. It is requ	losure provisions of 37 CFR § 1.56, there is hereby aminer may consider material to the examination of the ested that the Examiner make this information of recor of the subject application.
1.	Enclosures	accompanying this Inf	ormation Disclosure Statement are:
	1a.	Application publication English language color a PCT International English language translated to non-English Form PTO-1449. Explanations of Releproviding a concise of List of Copending Ap	y of a communication(s) from a foreign Patent Office
2. 🛚	This Infor		ement is filed under 37 CFR § 1.97(b):
		(Check elli	er Item 2a or 2b or 2c or 2d)

Serial No.: 10/602,636

3.	specified Action un	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND
		(Check either Item 3a or 3b; Item 3b to be checked if
	3a. 🗌	any reference known for more than 3 months) The § 1.97(e) Statement in Item 5 below is applicable; OR
	3b. 🗌	The \$180.00 fee set forth in 37 CFR § 1.17(p) is: ———————————————————————————————————
		to be charged to Deposit Account No. 19-3935.
4.		mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
5.	Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked) (Check either Item 5a or 5b)
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this
	5b. 🗌	Information Disclosure Statement. In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	This is a 0 1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §
		(Check appropriate Items 6a and/or 6b)
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).
	6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith

Serial No.: 10/602,636 7. \square This is a Request for Continued Examination under 37 CFR § 1.114. (Check either Item 7a or 7b) 7a. □ The Issue Fee has not been paid. 7b. □ A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively. 8. This is a Supplemental Information Disclosure Statement. (Check either Item 8a or 8b) 8a. \square This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on ___. A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on 8b. \square This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed ... understood to be the relevance of each non-English language publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d) satisfied for the non-English language publication(s) cited on the enclosed 9a. □ "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2) set forth in the application. 9b. satisfied for the non-English language publication(s) indicated on the 9c.

10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith). 37 CFR §§ 1.97(g) and (h).

(complete or relevant portion(s)) attached thereto.

enclosed as Attachment 1(e), hereto.

attached Form PTO-1449 as having an English language translation

9d. □

Serial No.: 10/602,636

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Dated: February 17, 2009

1201 New York Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 Paul F. Daebeler

Registration No. 35,852